Drug Profile
R 807
Alternative Names: R-807Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Radikal Therapeutics
- Class Antiglaucomas; Small molecules
- Mechanism of Action KATP channel stimulants; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Drops)
- 29 Nov 2019 Preclinical development for Glaucoma is ongoing in USA (Ophthalmic) (Radikal Therapeutics pipeline, November 2019)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Drops)